Applicability of an Assay for Routine Monitoring of Highly Variable Concentrations of Olanzapine Based on HPLC with Mass Spectrometric Detection

Clinical Chemistry

Volumn 49, Issue 12, 2003, Pages 2088-2091

  Gervasini, Guillermo ^a   Vizcaíno, Sonia ^a   Herráiz, Angustias G ^b   Benítez, Julio ^a   Carrillo, Juan Antonio ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b Psychiat Hosp Adolfo Diaz Ambrona   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BROMAZEPAM; CAFFEINE; CARBAMAZEPINE; CLONAZEPAM; CLOZAPINE; DIAZEPAM; DOXEPIN; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LEVOMEPROMAZINE; LORAZEPAM; MIDAZOLAM; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE;

ACCURACY; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CALIBRATION; CASE REPORT; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; REPRODUCIBILITY; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HUMANS; PIRENZEPINE; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 0344514854     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.022517     Document Type: Article

References (19)

1. Green B. Focus on olanzapine. Curr Med Res Opin 1999;15:79-85.
2. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J. Role of the smoking-induced CYP1A2 and polymorphic CYP2D6 in clinical response to olanzapine. J Clin Psychopharmacol 2003;23:119-27.
3. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003;25:46-53.
4. Boulton DW, Markowitz JS, DeVane CL. A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. J Chromatogr B Biomed Sci Appl 2001;759:319-23.
5. Llorca PM, Coudore F, Corpelet C, Buyens A, Hoareau M, Eschalier A. Integration of olanzapine determinations in a HPLC-diode array detection system for routine psychotropic drug monitoring. Clin Chem 2001;47:1719-21.
6. Olesen OV, Linnet K. Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs. J Chromatogr B Biomed Sci Appl 1998;714:309-15.
7. Dusci LJ, Peter Hackett L, Fellows LM, Ilett KF. Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection. J Chromatogr B Anal Technol Biomed Life Sci 2002;773:191-7.
8. Raggi MA, Casamenti G, Mandrioli R, Volterra V. A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure. J Chromatogr B Biomed Sci Appl 2001;750:137-46.
9. Aravagiri M, Ames D, Wirshing WC, Marder SR. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. Ther Drug Monit 1997;19:307-13.
10. Catlow JT, Barton RD, Clemens M, Gillespie TA, Goodwin M, Swanson SP. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1995;668:85-90.
11. Berna M, Shugert R, Mullen J. Determination of olanzapine in human plasma and serum by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 1998;33:1003-8.
12. Kollroser M, Schober C. Direct-injection high performance liquid chromatography ion trap mass spectrometry for the quantitative determination of olanzapine, clozapine and N-desmethylclozapine in human plasma. Rapid Commun Mass Spectrom 2002;16:1266-72.
13. Berna M, Ackermann B, Ruterbories K, Glass S. Determination of olanzapine in human blood by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2002;767:163-8.
14. Kassahun K, Mattiuz E, Nyhart E Jr, Obermeyer B, Gillespie T, Murphy A, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997;25:81-93.
15. Lohr JB, Flynn K. Smoking and schizophrenia. Schizophr Res 1992;8:93-102.
16. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37:177-93.
17. Bogusz MJ, Kruger KD, Maier RD, Erkwoh R, Tuchtenhagen F. Monitoring of olanzapine in serum by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 1999; 732:257-69.
18. Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit 1999;21:87-90.
19. Annesley TM. Ion suppression in mass spectrometry. Clin Chem 2003;49:1041-4.